MOLBIO DIAGNOSTICS LTD (MOLBIO) financials

MOLBIO DIAGNOSTICS LTD (MOLBIO) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Market Cap: ₹15,051Cr.
Current Price: ₹1,309
Stock P/E: 69.3
ROE: 13.8%
ROCE: 18.0%
Book Value: ₹
Dividend Yield: 0.00%
52W High / Low: ₹1,687/926

In Jun 2026, MOLBIO DIAGNOSTICS LTD (MOLBIO) reported sales ₹399 Cr and net profit ₹57 Cr.

Annual Mar 2026: sales ₹1,313 Cr, net profit ₹145 Cr.

Shareholding: Promoters 41.29% (Aug 2026), FIIs 1.51% (Aug 2026), DIIs 16.36% (Aug 2026), Government 0.02% (Aug 2026), Public 40.83% (Aug 2026).

MOLBIO quarterly results (₹ Cr.)
Category	Jun 2025	Mar 2026	Jun 2026
Sales	95	439	399
Expenses	105	332	308
Operating Profit	-10	107	92
OPM %	-10%	24%	23%
Other Income	1	3	1
Interest	2	9	9
Depreciation	7	10	8
Profit before tax	-17	91	76
Tax %	-23%	28%	25%
Net Profit	-13	66	57
EPS in Rs	-5.95	5.83	5.02
Raw PDF	—	—	—

MOLBIO profit and loss (₹ Cr.)
Category	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Sales	1,271	776	327	756	971	1,313
Expenses	676	457	286	552	746	1,061
Operating Profit	595	319	40	204	226	252
OPM %	47%	41%	12%	27%	23%	19%
Other Income	1	5	8	-21	-2	4
Interest	35	25	6	8	9	23
Depreciation	12	42	19	24	26	36
Profit before tax	549	258	23	152	188	198
Tax %	25%	27%	32%	27%	26%	27%
Net Profit	410	187	16	111	140	145
EPS in Rs	2,027.06	833.37	69.00	493.01	62.00	12.83
Dividend Payout %	-0%	-0%	-0%	-0%	-0%	-0%

MOLBIO balance sheet (₹ Cr.)
Category	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	2	2	2	2	2	11
Reserves	333	681	737	848	988	1,123
Borrowings	257	105	57	70	26	346
Other Liabilities	215	85	123	157	291	260
Total Liabilities	806	874	920	1,077	1,307	1,741
Fixed Assets	55	182	189	209	215	257
CWIP	100	-0	-0	2	18	6
Investments	9	9	54	54	95	317
Other Assets	643	683	676	813	980	1,160
Total Assets	806	874	920	1,077	1,307	1,741

MOLBIO cash flows (₹ Cr.)
Category	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	344	98	68	38	249	-38
Cash from Investing Activity	-142	-87	-51	-31	-98	-256
Cash from Financing Activity	-192	-20	31	-24	-17	292
Net Cash Flow	10	-9	48	-18	133	-2
Free Cash Flow	212	35	55	24	206	-74
CFO/OP	78%	53%	251%	39%	139%	6%

MOLBIO shareholding pattern (%)
Category	Aug 2026
Promoters	41.29%
FIIs	1.51%
DIIs	16.36%
Government	0.02%
Public	40.83%
No. of Shareholders	2,33,544

MOLBIO key ratios
Category	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	61	113	194	174	86	100
Inventory Days	261	402	885	393	395	286
Days Payable	124	64	201	129	226	130
Cash Conversion Cycle	198	450	877	438	254	256
Working Capital Days	75	206	479	239	155	143
ROCE %	—	41%	4%	22%	21%	18%

MOLBIOUpdated 30 Sept 2026, 20:31

Molbio Diagnostics Ltd

MOLBIOUpdated 30 Sept 2026, 20:31

Market Cap

₹15,051Cr.

Current Price

₹1,309

High / Low

₹1,687/926

Stock P/E

69.3

ROE13.8%

ROCE18.0%

Book Value₹

Face Value₹1.00

Dividend Yield0.00%

About

Molbio Diagnostics is an innovative point-of-care (POC) diagnostics company that develops affordable, rapid, and accurate diagnostic solutions for infectious and non-communicable diseases. Its flagship product, Truenat, is a portable, battery-powered PCR testing platform that delivers results withinan hour. Designed for use in resource-limited settings, it enables quick and decentralised disease diagnosis at the point of care.Through its wholly owned subsidiary,Bigtec Labs, Molbio has strong researchand development capabilities focused on creating diagnostic platforms for point-of-care (POC) testing. From product development to large-scale deployment, the company aimsto improve access to reliable and affordable healthcare for everyone.[1]

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2025	95	2	105	1	7	-17	-23	-13	-5.95
Mar 2026	439	9	332	3	10	91	28	66	5.83
Jun 2026	399	9	308	1	8	76	25	57	5.02

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2021	1271	35	676	1	12	549	25	410	2027.06
Mar 2022	776	25	457	5	42	258	27	187	833.37
Mar 2023	327	6	286	8	19	23	32	16	69
Mar 2024	756	8	552	-21	24	152	27	111	493.01
Mar 2025	971	9	746	-2	26	188	26	140	62
Mar 2026	1313	23	1061	4	36	198	27	145	12.83

Shareholding pattern

As of Aug 2026%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Government	Public
Aug 2026	41.29%	1.51%	16.36%	0.02%	40.83%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2021	2	333	257	215	806	55	100	9	643	806
Mar 2022	2	681	105	85	874	182	0	9	683	874
Mar 2023	2	737	57	123	920	189	0	54	676	920
Mar 2024	2	848	70	157	1077	209	2	54	813	1077
Mar 2025	2	988	26	291	1307	215	18	95	980	1307
Mar 2026	11	1123	346	260	1741	257	6	317	1160	1741

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2021	344	-142	-192	10
Mar 2022	98	-87	-20	-9
Mar 2023	68	-51	31	48
Mar 2024	38	-31	-24	-18
Mar 2025	249	-98	-17	133
Mar 2026	-38	-256	292	-2

Key ratios

Historical financial ratios

Category	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	61	113	194	174	86	100
Inventory Days	261	402	885	393	395	286
Days Payable	124	64	201	129	226	130
Cash Conversion Cycle	198	450	877	438	254	256
Working Capital Days	75	206	479	239	155	143
ROCE %	—	41%	4%	22%	21%	18%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of MOLBIO DIAGNOSTICS LTD (MOLBIO)?

The reported market capitalisation for MOLBIO DIAGNOSTICS LTD (MOLBIO) is ₹15,051Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of MOLBIO?

The current price shown for MOLBIO DIAGNOSTICS LTD (MOLBIO) on Fincrux is ₹1,309 with a 52-week high/low of ₹1,687/926.

What is the P/E ratio of MOLBIO DIAGNOSTICS LTD (MOLBIO)?

The stock P/E for MOLBIO DIAGNOSTICS LTD (MOLBIO) is 69.3 on Fincrux, with ROE at 13.8% and ROCE at 18.0%.

What were MOLBIO latest quarterly results?

For Jun 2026, MOLBIO DIAGNOSTICS LTD (MOLBIO) reported sales ₹399 Cr and net profit ₹57 Cr (figures in ₹ crore unless noted).

What are MOLBIO annual sales and net profit?

For Mar 2026, MOLBIO DIAGNOSTICS LTD (MOLBIO) shows sales of ₹1,313 Cr and net profit of ₹145 Cr on the Fincrux profit & loss statement.

Who owns MOLBIO DIAGNOSTICS LTD (MOLBIO)?

Latest shareholding for MOLBIO DIAGNOSTICS LTD (MOLBIO) on Fincrux: Promoters 41.29% (Aug 2026), FIIs 1.51% (Aug 2026), DIIs 16.36% (Aug 2026), Government 0.02% (Aug 2026), Public 40.83% (Aug 2026).

Where can I find MOLBIO DIAGNOSTICS LTD (MOLBIO) financials?

MOLBIO DIAGNOSTICS LTD (MOLBIO) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show MOLBIO balance sheet and cash flow?

Yes. The MOLBIO DIAGNOSTICS LTD (MOLBIO) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 30 September 2026 at 20:31